Adverse events of raltegravir and dolutegravir.

Fiche du document

Auteurs
Date

24 août 2017

Type de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1097/QAD.0000000000001590

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/28692533

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1473-5571

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_817F925D78593

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer

Mots-clés 0

Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents/administration & dosage; Anti-HIV Agents/adverse effects; Drug-Related Side Effects and Adverse Reactions/epidemiology; Female; HIV Infections/drug therapy; Heterocyclic Compounds, 3-Ring/administration & dosage; Heterocyclic Compounds, 3-Ring/adverse effects; Humans; Male; Mental Disorders/chemically induced; Mental Disorders/epidemiology; Middle Aged; Prospective Studies; Raltegravir Potassium/administration & dosage; Raltegravir Potassium/adverse effects; Switzerland; Withholding Treatment; Young Adult

Sujets proches En

Therapy

Citer ce document

L. Elzi et al., « Adverse events of raltegravir and dolutegravir. », Serveur académique Lausannois, ID : 10.1097/QAD.0000000000001590

Métriques

Partage / Export

Résumé 0

To compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir. Prospective cohort study. All antiretroviral therapy (ART)-naïve and ART-experienced HIV-infected individuals from the Swiss HIV Cohort Study who initiated raltegravir or dolutegravir between 2006 and 2015 were investigated concerning treatment modification within the first year. Of 4041 patients initiating ART containing raltegravir (n = 2091) or dolutegravir (n = 1950), 568 patients discontinued ART during the first year, corresponding to a rate of 15.5 [95% confidence interval (CI) 14.5-16.9] discontinuations per 100 patient-years. Only 10 patients on raltegravir (0.5%) and two patients on dolutegravir (0.1%) demonstrated virologic failure. The main reason for ART discontinuation was convenience expressed as patient's wish, physician's decision, or treatment simplification (n = 302). Toxicity occurred in 4.3% of patients treated with raltegravir and 3.6% with dolutegravir, respectively. In multivariable analysis, the only independent risk factor for discontinuing ART because of toxicity was female sex (hazard ratio 1.98, 95% CI 1.45-2.71, P 

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en